South Korea · Delayed Price · Currency is KRW DK Life Science Statistics
Total Valuation
DK Life Science has a market cap or net worth of KRW 118.02 billion. The enterprise value is 149.75 billion.
| Market Cap | 118.02B |
| Enterprise Value | 149.75B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
DK Life Science has 31.98 million shares outstanding. The number of shares has increased by 12.21% in one year.
| Current Share Class | 31.98M |
| Shares Outstanding | 31.98M |
| Shares Change (YoY) | +12.21% |
| Shares Change (QoQ) | -0.44% |
| Owned by Insiders (%) | 15.39% |
| Owned by Institutions (%) | 4.52% |
| Float | 11.96M |
Valuation Ratios
The trailing PE ratio is 13.42.
| PE Ratio | 13.42 |
| Forward PE | n/a |
| PS Ratio | 0.91 |
| PB Ratio | 0.90 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 272.16 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.70, with an EV/FCF ratio of -28.49.
| EV / Earnings | 17.30 |
| EV / Sales | 1.15 |
| EV / EBITDA | 7.70 |
| EV / EBIT | 11.48 |
| EV / FCF | -28.49 |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 0.30.
| Current Ratio | 1.72 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | 2.00 |
| Debt / FCF | -7.42 |
| Interest Coverage | 3.45 |
Financial Efficiency
Return on equity (ROE) is 7.32% and return on invested capital (ROIC) is 6.44%.
| Return on Equity (ROE) | 7.32% |
| Return on Assets (ROA) | 3.98% |
| Return on Invested Capital (ROIC) | 6.44% |
| Return on Capital Employed (ROCE) | 9.53% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 1.30B |
| Profits Per Employee | 86.58M |
| Employee Count | 100 |
| Asset Turnover | 0.64 |
| Inventory Turnover | 2.51 |
Taxes
In the past 12 months, DK Life Science has paid 2.17 billion in taxes.
| Income Tax | 2.17B |
| Effective Tax Rate | 20.04% |
Stock Price Statistics
The stock price has decreased by -19.52% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -19.52% |
| 50-Day Moving Average | 3,495.00 |
| 200-Day Moving Average | 3,987.95 |
| Relative Strength Index (RSI) | 60.57 |
| Average Volume (20 Days) | 481,943 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DK Life Science had revenue of KRW 130.34 billion and earned 8.66 billion in profits. Earnings per share was 275.00.
| Revenue | 130.34B |
| Gross Profit | 32.99B |
| Operating Income | 13.05B |
| Pretax Income | 10.83B |
| Net Income | 8.66B |
| EBITDA | 19.46B |
| EBIT | 13.05B |
| Earnings Per Share (EPS) | 275.00 |
Balance Sheet
The company has 7.25 billion in cash and 38.98 billion in debt, with a net cash position of -31.73 billion or -992.05 per share.
| Cash & Cash Equivalents | 7.25B |
| Total Debt | 38.98B |
| Net Cash | -31.73B |
| Net Cash Per Share | -992.05 |
| Equity (Book Value) | 131.37B |
| Book Value Per Share | 4,125.53 |
| Working Capital | 57.89B |
Cash Flow
In the last 12 months, operating cash flow was 433.65 million and capital expenditures -5.69 billion, giving a free cash flow of -5.26 billion.
| Operating Cash Flow | 433.65M |
| Capital Expenditures | -5.69B |
| Depreciation & Amortization | 6.41B |
| Net Borrowing | -8.89B |
| Free Cash Flow | -5.26B |
| FCF Per Share | -164.37 |
Margins
Gross margin is 25.31%, with operating and profit margins of 10.01% and 6.64%.
| Gross Margin | 25.31% |
| Operating Margin | 10.01% |
| Pretax Margin | 8.31% |
| Profit Margin | 6.64% |
| EBITDA Margin | 14.93% |
| EBIT Margin | 10.01% |
| FCF Margin | n/a |
Dividends & Yields
DK Life Science does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.21% |
| Shareholder Yield | -12.21% |
| Earnings Yield | 7.34% |
| FCF Yield | -4.45% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 7, 2025. It was a forward split with a ratio of 2.
| Last Split Date | Aug 7, 2025 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
DK Life Science has an Altman Z-Score of 2.39 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.39 |
| Piotroski F-Score | 5 |